Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Menopause
Interventions
DRUG

Estradiol and Progesterone

Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.

DRUG

Estradiol and Progesterone

Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period

Trial Locations (1)

03100

Centro A.F. de Estudios Tecnologicos, S.A., Mexico City

All Listed Sponsors
lead

Centro A.F. de Estudios Tecnologicos, S.A.

INDUSTRY

NCT00775242 - Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms. | Biotech Hunter | Biotech Hunter